Related Experiment Video
Updated: Jan 12, 2026

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Risk Factors Associated With Postoperative Complications Following Endovenous Laser Ablation for Varicose Veins
Aram Baram1, Raz Kamaran Hama Ali1, Chya Nasir Qadir1
1Branch of Clinical Sciences, College of Medicine, University of Sulaimani, Sulaymaniyah, Iraq.
Background:
Endovenous laser ablation (EVLA) is a widely accepted treatment for varicose veins, offering effective results with minimal invasiveness. However, postoperative complications remain a concern. This study examines risk factors associated with adverse outcomes and evaluates long-term clinical efficacy over 48 months.
Methods:
This retrospective, single-center study was conducted from January 2020 to January 2024 and included 500 patients with symptomatic varicose veins due to saphenous vein incompetence. All underwent preoperative clinical and duplex ultrasound evaluation; Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification; and Venous Clinical Severity Score (VCSS) scoring. Patients with postthrombotic syndrome, congenital malformations, or active DVT were excluded. EVLA using a 1470-nm laser was performed by an experienced vascular surgeon. Follow-up visits were scheduled periodically over 48 months. Primary outcomes included postoperative complications, while secondary outcomes focused on VCSS trends and patient satisfaction.
Results:
The cohort had a mean age of 38 years and was 56.8% female. Most were CEAP C4 or C5 with Grade 3 venous reflux. Minor complications included hematoma (6.4%), swelling (7.2%), infection (4%), and nerve injury (3.6%). Deep vein thrombosis occurred in 2% of patients; no pulmonary embolism or major cardiac events were reported. Endothermal heat-induced thrombosis occurred in 9%, with only 0.8% reaching Grade 3. Hypertension, diabetes, and obesity were associated with higher complication rates. By 48 months, all patients showed clinical improvement with VCSSs below 5.
Conclusions:
EVLA is a safe, effective treatment for varicose veins, even in advanced CEAP stages. Identifying patient-specific risk factors may help reduce complications and improve outcomes.
Related Concept Videos
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Varicose Veins I: Introduction
Esophageal Varices-I: Introduction
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis I: Introduction
Aneurysm IV: Nursing Management

